Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P900056/S225

ROTABLATOR Rotational Atherectomy System

Boston Scientific Corp · Decision date May 6, 2026

FDA DECISIONP900056/S225

What did the FDA decide?

FDA records P900056/S225 as a supplement to PMA P900056, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated May 6, 2026.

FDA approval order statement

the extension of maximum transfer time between preconditioning cell to sterilization chamber during routine production for Ethylene Oxide(EtO) sterilization
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
May 6, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P900056/S225
Regulatory pathway
PMA supplement
Product code
MCX
Decision code
OK30
Decision date
May 6, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: CATHETER, CORONARY, ATHERECTOMY.

Product code
MCX
FDA device class
3

For the original device and its historical approval scope, see PMA P900056. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P900056/S221 · Related supplement

    ROTABLATOR Rotational Atherectomy System

  2. P900056/S222 · Related supplement

    ROTAPRO Rotational Atherectomy System

  3. P900056/S223 · Related supplement

    ROTAPRO Rotational Atherectomy System

  4. P900056/S225 received

    Application receipt date recorded by FDA.

  5. P900056/S224 · Related supplement

    Rotablator; ROTAPRO Rotational Atherectomy Systems

  6. P900056/S225 · FDA decision

    30-Day Notice

  7. P900056/S228 · Related supplement

    ROTAPRO Rotational Atherectomy System

  8. P900056/S226 · Related supplement

    ROTAPRO Rotational Atherectomy Systems

  9. P900056/S229 · Related supplement

    ROTAPRO Rotational Atherectomy System

Timeline entries are records held by MedtechLedger for P900056. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P900056

Product / regulatory recordCompanyPathwayDecision dateSource
Boston Scientific CorpPMA approvalMay 28, 1993FDA
Boston Scientific CorpPMA supplementAug 14, 2025FDA
Boston Scientific CorpPMA supplementOct 27, 2025FDA
Boston Scientific CorpPMA supplementMar 5, 2026FDA
Boston Scientific CorpPMA supplementApr 9, 2026FDA
Boston Scientific CorpPMA supplementOct 20, 2026FDA
Boston Scientific CorpPMA supplementOct 21, 2026FDA
Boston Scientific CorpPMA supplementOct 21, 2026FDA

Explore the linked device profile

Other records with product code MCX

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Boston Scientific Corp

Headquarters
Not reported
FDA applicant address
Two Scimed Pl., Maple Grove, MN, 55311

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records